ScripScrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Takeda, F-star Sign Joint Research Pact
ScripWith investors closely watching how biopharmaceutical companies are spending the cash they have on hand so that they do not run out of money in a tough fundraising environment, even firms with revenue
ScripRivus Pharmaceuticals Inc. already had its lead Controlled Metabolic Accelerator (CMA), known as HU6, in a Phase IIa clinical trial last year when it raised $35m in series A venture capital. Now, wit
ScripDenmark’s biotech Orphazyme A/S is raising between $83m and $97m from an offering of American Depositary Shares (ADSs) on NASDAQ in the US and a private placement in Europe, as it nears the market w